FDA
-
-
-
-
-
-
-
Amarin Corp. (AMRN) Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
-
-
-
-
-
-
-
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
-
-
-
-
-
-
-
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
-
-
-
-
-
-
-
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
-
-
-
-
-
-
-
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
-
251,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All